@article{ref1,
title="United States drug courts and opioid agonist therapy: missing the target of overdose reduction",
journal="Forensic science international: mind and law",
year="2020",
author="Csete, Joanne",
volume="1",
number="",
pages="e100024-e100024",
abstract="Highlights  • Agonist therapy for opioid use disorder (OUD) is often inaccessible in the US at a time of high overdose mortality.  • OUD therapy could be offered by drug treatment courts as an alternative to criminal prosecution for some drug offenses.  • Many drug courts, however, reject gold-standard agonist therapies, seeing them as &quot;another form of addiction&quot;.  • Drug courts often prefer to offer extended-release naltrexone, but it is costly and requires pre-treatment abstinence.  • Drug courts have had limited success in improving access to OUD treatment at a time of high overdose mortality.<p /> <p>Language: en</p>",
language="en",
issn="2666-3538",
doi="10.1016/j.fsiml.2020.100024",
url="http://dx.doi.org/10.1016/j.fsiml.2020.100024"
}